Device Trial Radar · NCT06087718
Feasibility of the Maastro Applicator in Rectal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Aug 27, 2024
Primary completion
Oct 6, 2025
Study completion Oct 6, 2030
Sponsor
- Lead sponsor
- Maastricht Radiation OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Varian Medical Systems
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.
Conditions
- Rectal Cancer
- Feasibility
- Toxicity
- Quality of Life
- Radiation Toxicity
- Radiation Proctitis
- Brachytherapy
- Complete Response
Interventions
Maastro applicatorDevice
The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical feasibility of the Maastro boosting technique.Time frame: During treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maastro
Maastricht, Limburg, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.